



## **Auxellence Announces Update to Name Change, Share Consolidation and Up to \$1 Million Private Placement Financing**

VANCOUVER, BC, Friday, September 16<sup>th</sup>, 2016 – Auxellence Health Corporation (CSE: AID, OTCQB: AXHLF) (“Auxellence” or the “Company”) today announced that further to the September 15<sup>th</sup>, 2016 news release, the Company’s shares will be trading on a post consolidated basis and effecting the name and symbol change to EVITRADE Health Systems Corp., CSE:EVA on September 19<sup>th</sup>, 2016 with a record date of September 21<sup>st</sup>, 2016 instead of originally announced of being September 20<sup>th</sup>, 2016 for both dates. The Company’s new CUSIP is 30050R106 and the new ISIN is CA30050R1064. The Exchange “CSE” will issue a bulletin for any additional details.

The details for the non-brokered private placement financing for a minimum of \$500,000 to a maximum of \$1,000,000 CDN is expected to be announced after the close of trading on Tuesday, September 20<sup>th</sup>, 2016.

### **Contact:**

Sydney Au, CEO

Auxellence Health Corporation

Email: [ceo@auxellence.com](mailto:ceo@auxellence.com)

Phone: (604) 780-3311

Website: <http://www.auxellence.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/auxellence-health-corporation>

### **About Auxellence Health Corporation (CSE: AID, OTCQB: AXHLF)**

Auxellence was founded in 2013 to provide online services for resolving common health problems.

The company offers a physiologically interactive computing platform that integrates medical devices and artificial intelligence applications into a fully automated, personal health management system for hypertension, arrhythmia, diabetes, and obesity.

The current focus is on the normalization of cardiometabolic power in terms of blood pressure, blood glucose, and body weight – and the monitoring of the physiological response to medical solicitations, mainly medication, diet, exercise, and lifestyle changes.

### **About TULIP™**

The TULIP™ system is an online self-service intended for adults interested in normalizing blood pressure, heart rate and rhythm, blood glucose, and body weight. Measurement procedures, conditioning protocols, and session schedules are prescribed automatically from data acquired by the user’s TULIP™ device – a blood pressure monitor with interactive protocols that can feed medical records and expert systems useful in testing, tracking and treating common health conditions.

The Tulip™ medical device has received Health Canada and CE Mark certifications.



**AUXELLENC**

**Health Corporation**

**Disclaimers – Forward Looking Statements**

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators which is posted on [www.sedar.com](http://www.sedar.com), and on <http://thecse.com/en/listings/technology/auxellence-health-corporation>.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.